{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"95.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"97.5","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Endocrine dysfunction was assessed by growth hormone stimulation (GHS) tests. We report the percentage of patients with abnormal growth hormone stimulation tests.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the IFRT arms (Treatment Arms I, III, V)","id":"OG000","title":"Involved Field Radiation (IFRT)"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the PFRT arms (Treatment Arms II, IV, VI)","id":"OG001","title":"Posterior Fossa Radiation (PFRT)"}],"paramType":"NUMBER","populationDescription":"Only eligible \\& evaluable patients 3-7 years of age were included. Patients with anaplastic histology or disseminated/excess residual disease were not evaluable (NE). Availability of growth hormone stimulation test results were very limited. Only 3 out of 464 eligible and evaluable patients had this data available (2 PFRT patients and 1 IFRT).","reportingStatus":"POSTED","timeFrame":"Post-treatment up to 3 years","title":"Incidence of Endocrine Dysfunction as Measured by Growth Hormone Stimulation Tests at the Time of Completion of Therapy by Radiotherapy (RT) Group","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}